9,147 Shares in Stryker Corporation $SYK Bought by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH acquired a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the SEC. The firm acquired 9,147 shares of the medical technology company’s stock, valued at approximately $2,880,000.

Several other institutional investors also recently bought and sold shares of the company. Varma Mutual Pension Insurance Co raised its stake in shares of Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares in the last quarter. QRG Capital Management Inc. raised its position in Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after acquiring an additional 4,186 shares in the last quarter. Swedbank AB boosted its position in shares of Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after purchasing an additional 6,367 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research analyst reports. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Leerink Partners lowered their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Royal Bank Of Canada dropped their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Citizens Jmp decreased their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Trading Down 2.3%

Shares of SYK opened at $322.20 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a market capitalization of $123.58 billion, a PE ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The stock has a fifty day moving average of $328.64 and a two-hundred day moving average of $331.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last three months. 4.60% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.